Figure S1 PFU/cell or treated with different drug compounds to activate ER stress (Tunicamycin, Tunic.; 1µg/ml), DNA damage (Hydroxyurea, HU; 10mM) or apoptosis (Staurosporine, STS; 1µM). At 12h post infection/treatment, total cell lysates or total RNA were analyzed by western blot to detect SUMO2/3, phospho-Chk1 (marker for DNA damage), PARP (PARP cleavage marker of apoptosis), NS1, or actin protein levels, or RT-PCR to detect XBP1 splicing (marker of ER stress). (E) Immunofluorescent analysis of MRC5 cells stimulated with 10mM hydroxyurea for 12h, or infected with IAV for 12h. Cells were stained for phospho-histone H2AX (marker for DNA damage), NP and DNA (DAPI).
Scale bars represent 10µm. 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES

Cell-Lines and Compounds.
To generate A549 cells stably expressing TAP or TAP-SUMO proteins, sequences encoding TAP, TAP-SUMO1 or TAP-SUMO2 (ending in the C-terminal GG residues required for conjugation) were subcloned into the XhoI and XbaI sites of pEFIRES-P (Hobbs et al., 1998) to create pEFIRES-P/TAP, pEFIRES-P/TAP-SUMO1 or pEFIRES/TAP-SUMO2 expression vectors, respectively. Each construct was transfected into A549 cells, and individual clones stably expressing the desired proteins were selected using puromycin (1µg/ml) and validated by western blot. A549 cells stably expressing BVDV-NPro, PIV5-V or HCV-NS3/4A have been described previously (Chen et al., 2010; Hale et al., 2009; Killip et al., 2013) , and were generously provided by Rick Randall (University of St. Andrews, UK). Compounds used include: cycloheximide (Sigma, 50µg/ml), leptomycin B (Enzo Life Sciences, 11nM), zanamivir (Redx Pharma, 10µM), tunicamycin (Sigma, 1µg/ml), hydroxyurea (Sigma, 10mM), and staurosporine (Sigma, 1µΜ). Interferon (IFN) alpha, beta and gamma were purchased from Merck, Calbiochem and Roche, respectively, and used as indicated. TNFα was purchased from Prepotech and used at 10ng/ml. Cell viability was assessed using CellTiter-Glo® Luminescent Cell Viability Assay (Promega), according to the manufacturer's instructions. Nuclear-cytoplasmic fractionation was performed essentially as described (Sunters et al., 2010; Trilling et al., 2014) .
Immunofluorescence.
Cells on 13 mm coverslips were fixed, permeabilized and stained as described (Boutell et al., 2011) . Antibodies used are detailed below. DNA was stained using DAPI. Images were visualized on a Zeiss LSM 710 confocal microscope. For the mini-replicon reporter assay, pPolI-358-FFluc and pPolI-358-mCherry were generated in a manner similar to previous descriptions (Hoffmann et al., 2008) , and pCAGGS expression vectors encoding WSN PA, PB1, PB2 and NP, as well as pDZ-NP(WSN), have been described (Quinlivan et al., 2005; Zhang et al., 2012) . pCAGGS expression vectors encoding KAN-1 PB1, PB1-E445A/E446A, AvianPr-PB2-E627K, PA and NP were kindly provided by Martin Schwemmle (University of Freiburg, Germany) (Manz et al., 2012) . pmCherry-C1 was purchased from Clontech. Transfections were performed using FuGENE HD (Promega), with the ratio PA:PB1:PB2:NP:reporter being 1:1:1:10:10.
Antibodies.
Antibodies used for western blotting were: SUMO1 (Abcam, ab32058), SUMO2/3 
TAP Procedure and Mass Spectrometry.
Lysates were diluted 25x in order to dilute out the denaturing 2% SDS and passed over IgG sepharose (GE Healthcare), which was followed by enzymatic removal of the Protein A portion of the TAP-tag (see Fig. S3A ) using TEV protease (Promega). The resulting eluate was then affinity purified on calmodulin sepharose (GE Healthcare) followed by protein elution with buffer containing 10 mM EGTA, and protein recovery by precipitation with 100% TCA (w/v) and acetone washing. Purification resulted in ~25µg of protein sample that was resuspended in 30µl of 2x LDS sample buffer (Invitrogen).
Crude sample (~50µg) was also mixed 1:1 with 2x LDS sample buffer. Both purified and crude samples were resolved on NuPAGE Novex 10% Bis-Tris polyacrylamide gels using MOPS buffer (Invitrogen). Gel-fractionated proteins were stained with Coommassie blue and the gel was sliced into 13 sections as outlined in Fig. 3 . Protein slices were subjected to in-gel digestion with trypsin (Promega) essentially as described previously (Shevchenko et al., 2006) . The resulting peptide mixtures were vacuum-dried and resuspended in 30µl of 1% formic acid prior to analysis by LC-MS/MS on a Q Exactive mass spectrometer (Thermo Scientific) coupled to an EASY-nLC 1000 liquid chromatography system via an EASY-Spray ion source (Thermo Scientific) running at 75 µm x 500 mm at 45ºC on an EASY-Spray column. An elution gradient duration of 240 min was used. Data were acquired in the data-dependent mode. Full scan spectra (m/z 300-1800) were acquired with resolution R = 70,000 at m/z 400 (after accumulation to a target value of 1,000,000 with maximum injection time of 20 ms). The 10 most intense ions were fragmented by HCD and measured with a target value of 500,000, maximum injection time of 60 ms and intensity threshold of 1.7e3. A 40 second dynamic exclusion list was applied.
Quantitative Mass Spectrometry Data Analyses.
MaxQuant Analyses.
All raw files generated by MS analysis were processed with MaxQuant software (version 1.3.0.5) First, all MaxQuant-defined unwanted hits (e.g. 'reverse' (peptide sequences that would match other sequences if reversed), 'contaminants', and 'identified by site' (only identified by modification site)) as well as any remaining suspected internal contaminants (e.g. keratins, immunoglobulins, non-human origin proteins) were removed. All such prefiltered content was copied into 2 identical tabs and named 'Crude' and 'Purified'. In the 'Crude' list, all hits with 0 unique crude peptides and/or no crude ratios reported were removed. In the 'Purified' list, all hits with 0 unique purified peptides and/or no purified ratios reported were removed. Although MaxQuant uses built-in normalization algorithms to account for variable isotope purity/incorporation or error in lysate mixing, it is only applicable to values distributed in a unimodal Gaussian manner. We therefore applied an alternative method of normalization for our 'purified' data, which due to their highly purified nature and substantial changes in SUMOylation means they are not unimodal.
Given that the majority of proteins from our crude samples were unaffected by any treatment (Figs. S3D & S3E) , the median of the raw M/L, H/L, and H/M ratios for proteins was calculated and applied to normalize the raw ratios from crude samples as well as from corresponding TAP-purified samples. In order to calculate normalized values, raw ratios were divided by the normalization factors below:
factor H/L Next, log2 values of normalized ratios were calculated to facilitate further graphical representation of data in the form of tsMAPs (triple SILAC maps). We assumed that total abundance of the majority of the ~5000 proteins identified in crude lysates does not change significantly with treatment. Thus, the variable distribution of SILAC ratios in the 'crude' samples was deemed representative of the distribution of 'contaminants' in the 'purified' samples. We calculated the total abundance change of the 99% of all proteins closest to zero (log2 values) for all three SILAC ratios in our crude samples (see Figs. S3D & S3E), and used the maximum abundance change for these 99% of proteins as 'cut-off values' (table above) were defined as substrates with decreased SUMOylation (values stated in table above).
A search for ubiquitylation sites (GlyGly) was also included in the processing of the raw mass spectrometry data from purified samples. However, very few (~20) ubiquitylation sites were identified (Tables S1 & S2) , none of which were subsequently classified as SUMO substrates that change in abundance with IAV infection, and therefore were not followed-up in this study. Notably however, within our A549 SUMO-modified proteome, we identified ubiquitylation sites on ubiquitin itself at lysines 48 and 63. These sites may represent certain topologies of hybrid SUMO-ubiquitin chains (Praefcke et al., 2012) .
Manual Data Processing of 'Slice-by-Slice' Analyses to Confirm SUMO Modification.
For selected putative SUMO substrates, predicted molecular weight (preMW) was compared to their observed electrophoretic mobility (obsEM) in both 'crude' and 'purified' datasets. Such a method has been developed previously to confirm ubiquitin conjugation to target proteins (Peng and Cheng, 2005) . We assumed that a protein should run according mostly to its mass by SDS-PAGE, and should thus be detected within the gel slice (1-13) covering its approximate MW. For almost all proteins in crude lysates, the preMW was found to correspond to its obsEM when individual protein abundance in each gel slice was analyzed. However, bona fide covalent SUMO substrates would have an increased MW, and should therefore be detected in slices corresponding to larger masses.
The more highly modified the substrate, the larger the obsEM/preMW ratio should be.
This would be most apparent in TAP-SUMO-purified samples given that SUMO is usually only attached to a small proportion of the total population of a protein. Thus, for selected substrates, protein intensity values in individual gel slices from TAP-SUMOpurified material were compared between SILAC conditions. Raw intensity values for M and H data were normalized with the M/L and H/L normalization factors, respectively (table above). All three SILAC ratios were normalized as described for 'global' analyses.
Among all tested proteins with sufficient data, obsEM/preMW ratios were close to 1 for >95% of crude and contaminant proteins (no SUMO modification), while ratios for putative SUMO substrates were usually infinitely high (no protein observed at its preMW) for >95% of putative SUMO substrates. Protein intensities (abundance) and SILAC ratios within each slice were taken into account when creating graphical representations of these data as shown in Figs. 4B and S5.
Data Comparisons with Other Studies.
To compare SUMOylation responses between stresses, H/M ratios (i.e. treatment vs nontreatment) for SUMO substrates common to two different datasets were visualized on tsMAPs with Pearson's coefficient values indicated (Fig. 5) . All datasets were generated using the same or very similar experimental and data processing methodology (Fritah et al., 2014; Golebiowski et al., 2009; Tatham et al., 2011; Yin et al., 2012) . Comparison analyses were made with IPA (Ingenuity Pathway Analysis) software by matching respective gene names and ratios. To assess the reliability of our data, we also compared the substrates identified from the combined SUMO1 and SUMO2 IAV experiments in this study with either the respective crude lysate proteomes (this study) or lists of identified SUMO substrates from other studies (we first generated a database of SUMO substrates defined by publically-available proteomic studies either from our own laboratories or from independent groups (Barysch et al., 2014; Blomster et al., 2009; Fritah et al., 2014; Ganesan et al., 2007; Golebiowski et al., 2009; Hendriks et al., 2014; Matafora et al., 2009; Pungaliya et al., 2007; Rosas-Acosta et al., 2005; Schimmel et al., 2008; Tammsalu et al., 2014; Tatham et al., 2011; Vertegaal et al., 2006) ). Comparisons were performed and output collated from IPA software prior to results being depicted as Venn diagrams (Figure S3H-I ).
PCR-Based Analyses.
RT-qPCR.
Total RNA was isolated using the RNAeasy Plus Kit (Qiagen). RT-qPCRs were performed as a two-step process, and each sample was normalized to an endogenous control (18S rRNA or GAPDH). Complementary DNA (cDNA) was generated by reverse transcription of total RNA using TaqMan Reverse Transcription Reagents (Life Technologies) with an oligo dT primer. Reverse transcription reactions were as follows:
(i) primer annealing at 25°C for 10 min, (ii) strand elongation at 37°C for 1h, and (iii) CDC73 and ISG15 mRNA levels (see Figure 7A) were determined using the Sybr green RT-qPCR methodology as described previously (Lanz et al., 2015) . CDC73-specific primers (5-ACCATTTGCCTTGAACCTTG and 5-GGCCTAAACGTTCACCAAAA) and ISG15-specific primers (5-TGTCGGTGTCAGAGCTGAAG and 5-GCCCTTGTTATTCCTCACCA) were used.
Xbp1 Splicing Assay.
XBP1 mRNA levels were determined using the One-Step AccessQuick RT-PCR system 
Luciferase Reporter Assays.
Transfections were performed in 24-or 96-well plates using Fugene HD (Promega) or Lipofectamine 3000 (Life Technologies). pGL3-Mx1P-FFluc (ISRE-containing promoter), pNFκB-FFLuc (NFκB promoter) and p125-FFLuc (IFNβ promoter) have been described previously (Kochs et al., 2007) . pRL-SV40 (Promega) was used as an internal transfection/normalization control. Expression plasmids for GST and PIV5-V have been described previously (Hale et al., 2010; Kochs et al., 2007) . FLAG-SENP2 was a gift from Edward Yeh (Addgene plasmid #18047) (Kang et al., 2010) . The nucleotide sequences of CDC73 or mCherry were PCR amplified from existing pcDNA3-HRPT2
(gift from Matthew Meyerson (Addgene plasmid #11048) (Rozenblatt-Rosen et al., 2005)) or pmCherry-C1 vectors, respectively, and ligated in-frame into p3xFLAG-CMV-7.1 (Sigma-Aldrich) so as to express with N-terminal FLAG tags. Indicated CDC73 mutants were generated by Quikchange II Site-Directed Mutagenesis (Agilent Technologies) according to the manufacturer's instructions. Newly-generated constructs were authenticated by DNA sequencing.
Detection of Endogenous and Exogenous SUMOylated Proteins.
For detection of SUMOylated overexpressed CDC73, FLAG-tagged CDC73 constructs were co-transfected into 293T cells with pCAGGS expression vectors encoding 6His-tagged SUMO2-GG or 6His-tagged SUMO2-AA. Cells were harvested 36h posttransfection, and 6His-tagged SUMO proteins and conjugates were purified under denaturing conditions essentially as described previously ). To evaluate the SUMOylation status of endogenous proteins, cells were lysed in buffer containing 50mM Tris-HCl (pH 7.8), 650mM NaCl, 1% NP-40, 2% SDS, 5mM EDTA, and freshly supplemented with 20mM iodoacetamide, 10mM β-mercaptoethanol and cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail tablets (Roche). SDS levels were subsequently diluted to ~1% and β-mercaptoethanol levels to ~5mM. Lysates were then passed through a 29G needle six times. Following centrifugation at 14,000 rpm for 30 minutes at 10°C, soluble fractions were incubated with end-over-end mixing overnight at 4°C with either anti-SUMO1 (Abcam, ab32058) or anti-SUMO2/3 (Abcam, ab53194)
antibodies. Immune complexes were precipitated using Protein-G beads and washed extensively in buffer containing 50mM Tris-HCl (pH 7.8), 650mM NaCl, 1% NP-40, 0.1% SDS, 5mM EDTA, and freshly supplemented with 20mM iodoacetamide and cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail tablets (Roche). Purified proteins were eluted from the beads using 2X urea disruption buffer (6M urea, 2M β-mercaptoethanol, 4% SDS), and proteins of interest were detected by western blotting.
Statistical Analyses.
Statistical analyses were performed using an unpaired two-tailed Student's t-test. The p values for significance are stated in the figure legends.
Bioinformatic Pathway Analyses.
Bioinformatic pathway analyses were performed using the Enrichr platform (Chen et al., 2013 ).
